Senior insider sale
Chief R&D Officer at NEKTAR THERAPEUTICS — senior position signals high conviction
$26.4K
385.00 shares
What this filing means
ZALEVSKY JONATHAN plans to sell 385.00 shares of NEKTAR THERAPEUTICS valued at approximately $26.4K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 8/18/2026ACC: 0001959173-26-006172
Officer· Chief R&D Officer
Since Oct 2019
385.00
Shares to sell
$26.4K
Approx. market value
186.00
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months1
Restricted Stock Vesting
Compensation
8/14/2026
186.00Total acquired186.00
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/14/2026 | Restricted Stock Vesting Compensation | 186.00 | — |
| Total | 186.00 | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
199.00
Market value
$13.0K
5/19/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
186.00
Market value
$13.4K
8/18/2026
Total
Units
385.00
Value
$26.4K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
5/19/2026 | 199.00 | $13.0K | — | Completed |
| Planned — Approximate Date | ||||
8/18/2026 | 186.00 | $13.4K | NASDAQ | Planned |
| Total | 385.00 | $26.4K | ||